SIMRIS GROUP INTERIM REPORT JANUARY-MARCH 2026

About this update from Simris Group Ab Class B

QUARTER 1, JANUARY – MARCH 2026Net revenue increased by 167% to SEK 424k (159k).EBITDA improved by 41% to SEK -2 183k (-3 724k).EBIT/Operating result improved by 23% to SEK –5 626k (–7 288k).KEY EVENTS DURING THE QUARTERSimris Group enters into Memorandum of Understanding regarding divestment of assets in Hammenhög.Extraordinary General Meeting 19 January 2026 resolved to elect Julian Read as new board member, adopt new articles of association with increased share capital limits and share limits, and approve (i) a directed issue of units to investors at SEK 0.05 per unit, each unit consisting of one share and two warrant, corresponding to 140 905 267 units (ii) a directed issue of class B shares to management at SEK 0.05 per share, corresponding to 36 783 108 number shares.Simris evaluating options to expand its ADC-payload development programme and prepare for the next funding round to accelerate its plans.KEY EVENTS AFTER THE END OF THE QUARTERSimris Group advances divestment process for assets in Hammenhög by entering into a Memorandum of Understanding with a second prospective buyer, while the first prospective buyer remains engaged.CEO UPDATESince the last quarterly update, good progress has been made across our research and development programmes. Our commitment to advancing the next generation of antibody-drug conjugate (ADC) payloads remains unwavering, and the work underway demonstrates the breadth of innovation our team is delivering.We have now initiated studies on a number of new payload approaches, each designed to overcome key limitations in current ADC therapeutics and to unlock new clinical possibilities.Multi-Target Microcystin-ADC StudiesWe have initiated preclinical studies to evaluate its proprietary Microcystin-based ADC payload platform across selected solid tumour and haematologic cancer models. The studies use antibodies against established oncology targets and compare multiple Microcystin payload variants to assess their preclinical potency, selectivity and tolerability profiles. The results are expected to support data-driven lead-candidate selection and guide further development of the Microcystin-ADC platform.Advanced Payload InnovationWe have recently initiated an additional study that builds on the intellectual property of our ADC payload platform, exploring a novel approach to payload design within this framework. This study...

View stock analysis, news, and events for Simris Group Ab Class B